Fresenius' Ten-Year, 37-Slot Biosimilar Development Deal: WuXi Biologics Just Sold Its CDMO as a Pipeline Option

On 2 November 2026, Germany's Fresenius signed an exclusive development agreement with WuXi Biologics: exclusive options on up to 37 potential first-launch biosimilar candidates over ten years, expanding its pipeline from 29 to as many as 66 molecules across 13 therapeutic areas with more than 370 billion euros of originator list-price sales behind them — what the company calls the largest biosimilar development agreement ever announced. The structure is pure fee-for-service: no upfront, no fixed milestones, with all commercialisation rights and profits staying with Fresenius. One contract turns biosimilar outsourcing from single-asset deals into a portfolio of options.

On 2 November 2026, Fresenius announced an exclusive development agreement with WuXi Biologics. At its core is a menu of options: over the next ten years, Fresenius gains exclusive rights to select up to 37 potential first-launch biosimilar candidates, expanding its biosimilar pipeline from today's 29 molecules to as many as 66 across 13 therapeutic areas, against originator list-price sales of more than 370 billion euros — roughly 10 billion euros of originator revenue behind each slot. Fresenius calls it the largest biosimilar development agreement the industry has ever announced.

The structure matters more than the headline. This is not a licence deal and not a capacity contract; it is a fee-for-service development framework: no upfront payment, no fixed milestone total. Fresenius will exercise its options molecule by molecule — judging each on market attractiveness, development risk and expected returns — and pays WuXi Biologics a development service fee only for programmes it actually advances. WuXi's revenue tracks the exercise count.

The economics are equally clear: global exclusive commercialisation rights (including marketing authorisation holder status) and all commercial profits on every candidate belong to Fresenius — WuXi Biologics takes no royalty on sales. On manufacturing, Fresenius will set a long-term production strategy for each product individually and may progressively transfer output to its mAbxience network, while development runs on WuXi Biologics' global network across Europe, the US, China and Singapore.

The first two molecules stand behind undefended originators

Two molecules lead the list. The first is polatuzumab vedotin — Roche/Genentech's CD79b-directed ADC for diffuse large B-cell lymphoma, sold as Polivy. Roche's 2025 annual report shows global sales of 1.47 billion Swiss francs, up 38%, with first-line DLBCL alone above 1 billion francs. As of the signing date, no Polivy biosimilar has been approved by the EMA or FDA anywhere in the world; the US molecule patent expires in August 2029 with market exclusivity to June 2031, and the European patent runs to July 2033 under an SPC — implying first EU approval as early as 2028 and a US entry around 2031.

The second is teprotumumab — Amgen's Tepezza, the first approved targeted therapy for thyroid eye disease, with 2025 sales of 1.9 billion dollars, up 3%. As of October 2026, the US market still has no approved biosimilar. The shared logic is blunt: both are potential first-launch opportunities, and neither originator — Roche nor Amgen — is a traditional biosimilar defender. The first strikes land where the fortifications are thinnest.

For Fresenius: a decade-long ticket to 2035

Fresenius bought 55% of mAbxience in August 2022 and completed the purchase of the remaining 45% on 30 September 2026 for up to 750 million euros including a 50-million-euro contingent payment. mAbxience operates three drug-substance plants with more than 1,300 employees, generated over 320 million euros of revenue in 2025, and sells into more than 100 markets. With full ownership, Fresenius Kabi's Biopharma business now spans the complete value chain from research to commercialisation.

Fresenius cites IQVIA estimates that the addressable biosimilar market will grow roughly sixfold to more than 180 billion euros by 2035, excluding GLP-1 molecules. Its biopharma business generated about 900 million euros of revenue in 2025 with 51% organic growth; the 2030 targets set in December 2025 — roughly doubling revenue from 2025 at around a 20% EBIT margin — explicitly treat this agreement as incremental, and the company says it will raise its long-term biopharma ambitions accordingly. The deal is funded from operating cash flow, requires no new financing, and leaves the 2026 guidance unchanged.

For WuXi Biologics: turning the D into piece-rate cash flow

For WuXi Biologics, the accounting implication outweighs the narrative. Biosimilar development success rates are materially higher than for novel biologics, and the exercise rhythm across 37 options belongs to the client — meaning WuXi has converted a decade of development demand from case-by-case negotiation into work inside a framework, billed by the job. Sell-side commentary expects the related revenue to migrate from the D (development) side toward the M (manufacturing) side: even where commercial production ultimately shifts to mAbxience, clinical supplies, process development and tech-transfer revenue stays inside the WuXi system.

It is also a textbook hybrid contracting structure for the Section 232 era: development and manufacturing are separated at the contract level, with production strategy set product by product. Generics and biosimilars already sit on the zero-tariff side of the pharma tariff schedule — a point we examined when the tariffs went live — so clients enjoy rare freedom on siting: develop where the network is most proven, manufacture where the tariff math is best. The two decisions no longer have to share a map.

What it means for the industry: biosimilar outsourcing goes portfolio

The most durable lesson of this deal is that it changes the unit of pricing in biosimilar outsourcing from a programme to an option portfolio. For a decade the standard biosimilar BD move was a single-asset licence or a single-site capacity contract; Fresenius has just locked exclusive options on 37 slots, pre-booking the industry's scarcest asset — development capacity with clean FDA and EMA inspection records — into its own decade-long schedule.

That squares with the FDA's pivot in biosimilar regulation that we tracked earlier — less weight on clinical equivalence, more on CMC. When review shifts toward process and quality data, development capability is itself the gate. For every other biologics CDMO, the question is no longer whether to serve biosimilars but whose inspection record can support a ten-year option list.